References


References


References

11.


Davies SW, Marchant B, Lyons JP, et al. Irregular coronary lesion morphology after thrombolysis predicts early
References


de Bono DP, et al. for the European Cooperative Study Group. Effect of early intravenous heparin on coronary
patency, infarct size, and bleeding complications after alteplase thrombolysis: a result of a randomized double

Delanty N, Fitzgerald DJ. Subcutaneous heparin during coronary thrombolysis. Too little, too late. Circulation

Deutsch E, Fischer M, Marschner I, Kock M. Die Wirkung intravenös applizierter Streptokinase auf Fibrinolyse

Deutsch E, Rao AK, Colman RW. Selective thrombin inhibitors: The next generation of anticoagulants. J Am

DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total
coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-
902.

Dykewicz MS, McGrath KG, Davison R, Kaplan KJ, Patterson R. Identification of patients at risk for

Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is

Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein a inhibits streptokinase-mediated activation of

Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator

Eisenberg PR, Sherman LA, Schectman K, Sobel BE, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker

Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by

Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for

Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of

Elliot JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years

Ellis SG, Topol EJ, George BS, et al. Recurrent ischemia without warning. Analysis of risk factors for in-
hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator.

Endert E, Delemarre BJM, Sanders GTB. De latex-agglutinatiest voor myoglobine bij het acute hartinfarct. Ned
Tijdschr Geneeskd 1987;131:1309-11.

Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of


References


Gil V, Antunes A, Ventosa A, Morais J, Seabra-Gomes R, on behalf of the Portuguese Cooperative Group on Ventricular Function of the LATE Study. Late thrombolysis with alteplase improves left ventricular ejection fraction at 1 month after myocardial infarction - a double blind, placebo controlled study. J Am Coll Cardiol 1993;21:300A.


40
References


Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847-51.


References


42


Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen
References


LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.

Lee HS, Cross S, Davidson R, Reid T, Jennings K. Raised levels of antistreptokinase antibody and neutralization titers from 4 days to 54 months after administration of streptokinase or anistreplase. Eur Heart J 1993;14:84-9.


**References**


Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.


Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for myocardial infarction. Lancet 1993;341:1574-7.

References


Shah PK. The role of thrombolytic therapy in patients with acute myocardial infarction presenting later than six hours after the onset of symptoms. Am J Cardiol 1991;68:72C-77C.


Silver MD, Baroldi G, Mariani F. The relationship between acute occlusive coronary thrombi and myocardial
References


Toffler GH, Brezinski D, Schager AI, et al. Concurrent morning increase in platelet aggregability and the risk of
References


Verstraete M. Intravenous administration of a thrombolytic treatment is the only realistic therapeutic approach in evolving myocardial infarction. Eur Heart J 1985;6:586-93.


Weaver DW, Cerqueira M, Hallstrom AP, et al. for the myocardial infarction triage and intervention project group. Prehospital-initiated vs hospital-initiated thrombolytic therapy -The myocardial infarction triage and intervention (MITI) trial. JAMA 1993;270:1211-6 (a).


